MedTrace Logo

A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects

NCT01288157 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-05-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics of golimumab in Chinese male participants.

Conditions

  • Healthy Adult Chinese Males

Interventions

DRUG

Golimumab

Single dose of 100 mg subcutaneously

DRUG

Golimumab

Single dose of 50 mg subcutaneously

Sponsors & Collaborators

  • Centocor, Inc.

    lead INDUSTRY

Principal Investigators

  • Centocor, Inc. Clinical Trial · Centocor, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01288157 on ClinicalTrials.gov